2013-27: Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve clinical significant concentrations of dabigatran and thrombin inhibiting activity in vitreous and subretinal fluid?
Investigator Initiated Research
Inclusion stopped on 22-2-2015
Coagulation factor thrombin is thought to play an important role in the development of proliferative vitreoretinopathy (PVR). The direct thrombin inhibitor dabigatran is therefore an interesting potential drug candidate. It is investigated whether oral administration of dabigatran etexilate in patients with a rhegmatogenous retinal detachment leads to clinical significant dabigatran levels and thrombin inhibiting activity in the vitreous and subretinal fluid.